After nine months, drugs sales increased from $62M to $77.2M without its former salesforce.ĪSRT possesses an A+ growth grade, and Q4 2021 delivered top-line growth of 7% despite its discontinuation of a product line, and adjusted EBITDA reflects an increase of 118% compared to the previous year. This represents growth of 15% to 24% on the top line and 31% to 47% in EBITDA,” said Daniel Peisert, ASRT President and CEO, during the Q4 Earnings Call.ĪSRT Profitability Grade (Seeking Alpha Premium)Īfter implementing a digital strategy whereby ASRT restructured, got rid of its salesforce, and focused only on a digital sales model, it successfully sold its financially draining opioid business Nucynta, ASRT is cashing in. “We expect to generate net product sales of $126 million to $136 million and adjusted EBITDA of $64 million to $72 million in 2022. After years of declining revenues, this company is on the upward trend, following three guidance raises and strong growth and profitability. ( ASRT) is crushing the healthcare industry and, according to our Quant Rankings, ranks #1 in the industry out of 202 and #2 in its sector. Specialty pharmaceutical company Assertio Holdings, Inc. These essential qualities are currently found in my top 5 stocks under $10 to buy now. The key is finding companies with the attractive collective financial traits we seek solid valuation, strong growth, EPS revisions, profitability, and momentum. Although past performance is not a guarantee of future results, some of my small-cap picks have paid out handsomely over the last year based on our Quant System. However, small-caps have outperformed large-cap stocks over long periods, which is why I wrote a Forbes article on the subject a few years ago. As a result, stocks under $10 are not an investment for everyone, particularly the risk-averse, given their volatility. Additionally, small-caps typically sell off more from a day-to-day trading perspective than large-cap stocks when the market begins to enter a slowdown, recession, or contraction. Small-cap stocks with a lot of leverage tend to sell off sharply when threatened by rising interest rates. Small-caps tend to go through high growth periods and typically have higher leverage. Because they are smaller in size and come with increased volatility and responsibility, they are among the riskiest of U.S. Small-Cap stocks are smaller-sized companies with a market capitalization between $300 million and $2 billion, offering excellent opportunities for long-term growth. Top Stocks Under $10 Screener (Seeking Alpha Premium) 5 Cheap Stocks Under $10 To Invest In Although this screen is currently heavily weighted with energy stocks, our intent of the recommendations is to offer a diversified base of stocks under $10. While I generally do not recommend stocks under $10, the key to smart investing is identifying stocks that possess strong fundamentals and, in this case, are coupled with low prices. The expectation for earnings growth of Russell 2000 companies in 2022 is 30%, well above the 9% forecast for the S&P 500.” Our favorite picks throughout this article are all Strong Buys, selected from the Seeking Alpha screen called Top Stocks Under $10. For more than a decade, small-cap stocks have outperformed large-cap stocks, and according to Goldman Sachs analysts, “We believe small-cap stocks can continue to outperform in 2022. Darren415/iStock via Getty Images A Look Ahead at Small-Cap Stocks in 2022įear of what’s in store for the future has created a pullback in the markets, creating potential buying opportunities for investors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |